Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABBV AbbVie	$215.42 +1.1%	$208.27	$181.73 ▼ $244.81	$376.54B	0.32	5.72 million shs	4.64 million shs
LLY Eli Lilly and Company	$1,085.36 +1.9%	$948.23	$623.78 ▼ $1,133.95	$1.00T	0.48	3.34 million shs	2.58 million shs
LVS Las Vegas Sands	$51.09 +2.7%	$53.28	$40.03 ▼ $70.45	$32.97B	0.85	4.60 million shs	3.78 million shs
PFE Pfizer	$26.24 +1.5%	$26.82	$23.06 ▼ $28.75	$147.33B	0.35	33.58 million shs	38.98 million shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABBV AbbVie	+1.24%	+1.37%	+9.22%	-4.11%	+16.12%
LLY Eli Lilly and Company	+1.74%	+6.82%	+24.96%	+6.18%	+49.76%
LVS Las Vegas Sands	+2.66%	+2.86%	-6.11%	-8.47%	+22.94%
PFE Pfizer	+1.47%	+1.80%	-2.14%	-3.21%	+11.14%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABBV AbbVie	$215.42 +1.1%	$208.27	$181.73 ▼ $244.81	$376.54B	0.32	5.72 million shs	4.64 million shs
LLY Eli Lilly and Company	$1,085.36 +1.9%	$948.23	$623.78 ▼ $1,133.95	$1.00T	0.48	3.34 million shs	2.58 million shs
LVS Las Vegas Sands	$51.09 +2.7%	$53.28	$40.03 ▼ $70.45	$32.97B	0.85	4.60 million shs	3.78 million shs
PFE Pfizer	$26.24 +1.5%	$26.82	$23.06 ▼ $28.75	$147.33B	0.35	33.58 million shs	38.98 million shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABBV AbbVie	+1.24%	+1.37%	+9.22%	-4.11%	+16.12%
LLY Eli Lilly and Company	+1.74%	+6.82%	+24.96%	+6.18%	+49.76%
LVS Las Vegas Sands	+2.66%	+2.86%	-6.11%	-8.47%	+22.94%
PFE Pfizer	+1.47%	+1.80%	-2.14%	-3.21%	+11.14%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABBV AbbVie	2.88	Moderate Buy	$253.43	17.64% Upside
LLY Eli Lilly and Company	2.87	Moderate Buy	$1,227.00	13.05% Upside
LVS Las Vegas Sands	2.61	Moderate Buy	$68.28	33.64% Upside
PFE Pfizer	2.19	Hold	$28.61	9.04% Upside

Current Analyst Ratings Breakdown

Latest LLY, ABBV, PFE, and LVS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/27/2026	PFE Pfizer	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral	$27.00
5/26/2026	LVS Las Vegas Sands	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold (C+) ➝ Hold (C)
5/26/2026	LLY Eli Lilly and Company	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$1,133.00 ➝ $1,251.00
5/26/2026	LLY Eli Lilly and Company	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$1,119.00
5/22/2026	LLY Eli Lilly and Company	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$1,283.00
5/21/2026	LLY Eli Lilly and Company	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$1,350.00
5/21/2026	LLY Eli Lilly and Company	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform
5/21/2026	LLY Eli Lilly and Company	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target		$1,300.00 ➝ $1,330.00
5/19/2026	LLY Eli Lilly and Company	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy (B) ➝ Buy (B-)
5/15/2026	ABBV AbbVie	Evercore Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$235.00
5/14/2026	PFE Pfizer	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Underperform	$26.00

(Data available from 5/28/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABBV AbbVie	$61.16B	6.22	$15.31 per share	14.07	($3.74) per share	-57.60
LLY Eli Lilly and Company	$65.18B	15.68	$25.62 per share	42.36	$33.13 per share	32.76
LVS Las Vegas Sands	$13.02B	2.60	$5.59 per share	9.14	$2.43 per share	21.03
PFE Pfizer	$62.58B	2.39	$4.46 per share	5.88	$15.86 per share	1.65

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABBV AbbVie	$4.23B	$2.03	106.12	13.22	0.74	5.79%	-576.45%	13.39%	7/30/2026 (Estimated)
LLY Eli Lilly and Company	$20.64B	$28.15	38.56	24.48	1.16	34.98%	105.77%	23.76%	8/5/2026 (Estimated)
LVS Las Vegas Sands	$1.63B	$2.70	18.92	13.88	1.13	13.41%	118.27%	10.52%	7/22/2026 (Estimated)
PFE Pfizer	$7.77B	$1.31	20.03	9.17	N/A	11.83%	19.44%	8.41%	8/4/2026 (Estimated)

Latest LLY, ABBV, PFE, and LVS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/5/2026	Q1 2026	PFE Pfizer	$0.7220	$0.75	+$0.0280	$0.47	$13.84 billion	$14.45 billion
4/30/2026	Q1 2026	LLY Eli Lilly and Company	$6.97	$8.55	+$1.58	$8.26	$17.82 billion	$19.80 billion
4/29/2026	Q1 2026	ABBV AbbVie	$2.59	$2.65	+$0.06	$0.39	$14.72 billion	$15.00 billion
4/22/2026	Q1 2026	LVS Las Vegas Sands	$0.7560	$0.91	+$0.1540	$0.85	$3.32 billion	$3.59 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABBV AbbVie	$6.92	3.21%	+6.80%	340.89%	53 Years
LLY Eli Lilly and Company	$6.92	0.64%	+15.18%	24.58%	11 Years
LVS Las Vegas Sands	$1.20	2.35%	+4.83%	44.44%	2 Years
PFE Pfizer	$1.72	6.55%	-13.20%	131.30%	16 Years

Latest LLY, ABBV, PFE, and LVS Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
4/22/2026	PFE Pfizer	quarterly	$0.43	6.71%	5/8/2026	5/8/2026	6/12/2026
5/4/2026	LLY Eli Lilly and Company	quarterly	$1.73	0.69%	5/15/2026	5/15/2026	6/10/2026
4/21/2026	LVS Las Vegas Sands	quarterly	$0.30	2.3%	5/5/2026	5/5/2026	5/13/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABBV AbbVie	N/A	0.80	0.68
LLY Eli Lilly and Company	1.26	1.50	1.10
LVS Las Vegas Sands	8.64	0.92	0.91
PFE Pfizer	0.67	1.25	0.94

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABBV AbbVie	70.23%
LLY Eli Lilly and Company	82.53%
LVS Las Vegas Sands	39.16%
PFE Pfizer	68.36%

Insider Ownership

Company	Insider Ownership
ABBV AbbVie	0.06%
LLY Eli Lilly and Company	0.14%
LVS Las Vegas Sands	0.55%
PFE Pfizer	0.62%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABBV AbbVie	57,000	1.77 billion	1.77 billion	Optionable
LLY Eli Lilly and Company	50,000	941.74 million	940.42 million	Optionable
LVS Las Vegas Sands	41,500	662.64 million	658.99 million	Optionable
PFE Pfizer	75,000	5.70 billion	5.66 billion	Optionable

LLY, ABBV, PFE, and LVS Headlines

Recent News About These Companies

Geode Capital Management LLC Has $3.24 Billion Stock Holdings in Pfizer Inc. $PFE

3 hours ago | marketbeat.com

Pfizer (NYSE:PFE) Shares Up 1.5% - Should You Buy?

May 27 at 5:36 PM | marketbeat.com

How Did AbbVie's Oncology Portfolio Perform in Q1 Despite Headwinds?

May 27 at 2:19 PM | finance.yahoo.com

Pfizer’s Next-Gen Infant Pneumococcal Vaccine Trial: What Investors Should Watch Now

May 27 at 1:10 PM | tipranks.com

Pfizer Steps Up Obesity Push With New Phase 3 Berobenatide Trial

May 27 at 1:10 PM | tipranks.com

Pfizer Bets on New & Acquired Drugs to Offset Its LOE Pressure?

May 27 at 9:55 AM | zacks.com

BofA Raises Price Target on Pfizer (PFE) Following Strong Q1 Results

May 27 at 9:18 AM | finance.yahoo.com

BofA Raises Price Target on Pfizer (PFE) Following Strong Q1 Results

May 27 at 8:10 AM | insidermonkey.com

Wealth Advisors of Tampa Bay LLC Lowers Holdings in Pfizer Inc. $PFE

May 27 at 7:16 AM | marketbeat.com

King Luther Capital Management Corp Sells 117,825 Shares of Pfizer Inc. $PFE

May 27 at 6:53 AM | marketbeat.com

Pfizer Inc. $PFE Shares Sold by Optimist Retirement Group LLC

May 27 at 6:34 AM | marketbeat.com

3 Dividend Stocks Yielding Above 5% to Scoop Up Now

May 27 at 4:17 AM | barchart.com

Is Pfizer Inc. (PFE) One of the Best Medical Stocks to Invest in According to Billionaires?

May 26 at 5:20 PM | finance.yahoo.com

Thinning revenues: inside the $14bn Eliquis patent cliff

May 26 at 5:20 PM | pharmaceutical-technology.comP

If Viking Therapeutics Is Acquired, Here's Who Wins

May 26 at 8:50 AM | 247wallst.com

Arnhold LLC Raises Stock Holdings in Pfizer Inc. $PFE

May 26 at 3:24 AM | marketbeat.com

How The Investment Narrative For Pfizer (PFE) Is Shifting On Pipeline Hopes And Revenue Risks

May 26 at 1:10 AM | finance.yahoo.com

[Latest] Global Bioprocess Automation Software Market Size/Share Worth USD 6.19 Billion by 2035 at a 14 CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)

May 26 at 1:10 AM | finance.yahoo.com

Pfizer’s Abrocitinib Atopic Dermatitis Study Nears Data Milestone: What Investors Should Watch

May 25 at 8:09 PM | theglobeandmail.com

This Healthcare Stock With 6%-Plus Yield: Is the Dividend Safe?

May 25 at 5:15 PM | fool.com

MRK Stock Gains After CHMP Backs Keytruda Combo for Bladder Cancer

May 25 at 2:28 PM | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

LLY, ABBV, PFE, and LVS Company Descriptions

AbbVie NYSE:ABBV

$215.42 +2.30 (+1.08%)

Closing price 05/27/2026 03:59 PM Eastern

Extended Trading

$215.10 -0.32 (-0.15%)

As of 07:15 AM Eastern

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Eli Lilly and Company NYSE:LLY

$1,085.36 +20.62 (+1.94%)

Closing price 05/27/2026 03:59 PM Eastern

Extended Trading

$1,088.75 +3.39 (+0.31%)

As of 07:17 AM Eastern

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Las Vegas Sands NYSE:LVS

$51.09 +1.34 (+2.70%)

Closing price 05/27/2026 03:59 PM Eastern

Extended Trading

$50.93 -0.16 (-0.32%)

As of 07:13 AM Eastern

Las Vegas Sands Corp., together with its subsidiaries, develops, owns, and operates integrated resorts in Macao and Singapore. It owns and operates The Venetian Macao Resort Hotel, the Londoner Macao, The Parisian Macao, The Plaza Macao and Four Seasons Hotel Macao, Cotai Strip, and the Sands Macao in Macao, the People's Republic of China; and Marina Bay Sands in Singapore. The company's integrated resorts feature accommodations, gaming, entertainment and retail malls, convention and exhibition facilities, celebrity chef restaurants, and other amenities. Las Vegas Sands Corp. was founded in 1988 and is based in Las Vegas, Nevada.

Pfizer NYSE:PFE

$26.24 +0.39 (+1.51%)

Closing price 05/27/2026 03:59 PM Eastern

Extended Trading

$26.16 -0.08 (-0.32%)

As of 07:17 AM Eastern

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest LLY, ABBV, PFE, and LVS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest LLY, ABBV, PFE, and LVS Earnings

Compare Dividends

Latest LLY, ABBV, PFE, and LVS Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

LLY, ABBV, PFE, and LVS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

LLY, ABBV, PFE, and LVS Company Descriptions

AbbVie NYSE:ABBV

Eli Lilly and Company NYSE:LLY

Las Vegas Sands NYSE:LVS

Pfizer NYSE:PFE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools